UNS - Unilife Corporation

[Sean K]

http://seekingalpha.com/article/113...hort-squeeze?source=email_rt_article_readmore


An Interview With Unilife's CEO: A Long-Term Opportunity And A Looming Short Squeeze
January 25, 2013 | about: UNIS

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)

By Ivan Deryugin

The author is an intern, still at university.

His LinkIn profile summary:

I currently attend Vanderbilt University, where I am double majoring in economics & political science, with a minor in corporate strategy. I have been trading equities and options for the past 5 years, and founded Helix Investment Management in July 2011 to pay for my educational expenses, as well as manage my family's assets. I publish equity research for Seeking Alpha and PropThink, and am currently an asset management intern at Mastrapasqua Asset Management, where I cover the life science and biotechnology sectors.

He looks at least 19.

 

[pacestick]

Do you have aproblem with a uni student working their way through college In a field related to their studies

 

[pacestick]

Do you have aproblem with a uni student working their way through college In a field related to their studies

If you do you can always use the hyperlink at the bottom of the article to submit your own

 

[Sean K]

If you do you can always use the hyperlink at the bottom of the article to submit your own

Others have responded to his article. Scroll down and you find a critical analysis of AS and his not so brilliant career.

 

[Sean K]

Letter to shareholders today.

Again sprewking $1b in sales in the not too distant future.

From $10m losses a quarter to $1b in revenue in the flashes of flashes.

This is going to end in tears.

January 31, 2013
Dear Fellow Shareholders

We look forward to finalizing negotiations with multiple pharmaceutical companies for a series of contracts throughout 2013.

Due to the strong relationships we have established with more than 40 new and prospective customers, including many of the 20 largest pharmaceutical companies in the world, we believe that these prospective agreements in 2013 will simply pave the way for even greater things to come. Most of these pharmaceutical companies have advised that they are targeting our devices for use with multiple approved and late-stage pipeline drugs. As each of these target drugs reaches peak annual commercial sales in future years, we expect to have a series of long-term contracts that will collectively generate recurring, potential revenues in excess of $1 billion a year with attractive operating margins. Our commercial pipeline continues to diversify beyond these active programs, with additional evaluations commencing with ten prospective new customers this month alone.

Can't name the pharma companies though...

I think we've read these promises before. Like back when it was an Australian based company but had to leave.

 

[Garpal Gumnut]

Letter to shareholders today.

Again sprewking $1b in sales in the not too distant future.

From $10m losses a quarter to $1b in revenue in the flashes of flashes.

This is going to end in tears.



Can't name the pharma companies though...

I think we've read these promises before. Like back when it was an Australian based company but had to leave.

Agree kennas.

This is to on first inspection a dawg on the chart.

However it is trending sideways and has a modicum of support at the 0.35-0.37 level level.

Should it drift closer to 0.30 I'd be out, but there is some support at present prices so a move beyond 0.50 with good volume may represent a good entry.

I have no idea what they do and care less.

Just a charting opinion.

gg

 

[pacestick]

 

[Sean K]

View attachment 50787

Stick, I'm not sure what this is showing?

There's a little yellow line going up against some support is there?

 

[pacestick]

I think its a nasdaq reaction to the letter i.e. a small number of shorts have withdrawn as they were counting on further share issues . I dont believe that it is a short squeeze start just a sort of reset at a higher price. The company need several positive cash flow results to compund the effect and while they are coming I cant see it before easter. My point in posting it which I copied from a nasdaq poster is that it should result in a simmilar result today on the ASX

 

[pacestick]

http://carpedmstocks.blogspot.com.au/2013/02/unis-jpmorgan-adds-boatload.html


$UNIS - JPMorgan Adds a Boatload

JP Morgan Chase & Co. just filed a form schedule 13-d http://www.sec.gov/Archives/edgar/data/19617/000001961713000178/Unlifecorp.htm for its holdings in $UNIS. They have added an additional 1 million + shares to their holdings and now hold 8.8% of the company's stock. Other funds continue to add and there are a few newcomers as well. While the Nasdaq site hasn't updated to show this information, another major fund made an initial purchase of over 600,000 shares. This just bodes the question, at what point will the shorts be shorting shares that they have already shorted. Its possible this is already happening. Much of their enthusiasm is probably predicated on the logic that the company will report a similar quarter as the previous ones and that they'll be able to get weak hands to sell out with some pressure. The selling pressure of late has been met with equally strong buying pressure. The shares trading on the Nasdaq have been in a very narrow range. For the sake of simplicity if we assume that 42 million shares are available for trading on Nasdaq. Out of that 42 million shares, I estimate that 32 million are held by funds leaving 10 million shares left for the hoi polloi. Shorters have already sold over 10 million shares, which means that should there be any kind of news that generates real excitement, ie, revenue generation or supply contracts, they will be competing for an ever shrinking number of shares. Many will continue to short all the way up hoping that the stock will fall after the excitement dies down, but with so few shares truly available, they will have no place to go but back into the market. We know that the PR machine is primed and ready to go once the company is ready to announce some big news. The countdown clock may have already started.

 

[Sean K]

http://carpedmstocks.blogspot.com.au/2013/02/unis-jpmorgan-adds-boatload.html


$UNIS - JPMorgan Adds a Boatload

JP Morgan Chase & Co. just filed a form schedule 13-d http://www.sec.gov/Archives/edgar/data/19617/000001961713000178/Unlifecorp.htm for its holdings in $UNIS. They have added an additional 1 million + shares to their holdings and now hold 8.8% of the company's stock. Other funds continue to add and there are a few newcomers as well. While the Nasdaq site hasn't updated to show this information, another major fund made an initial purchase of over 600,000 shares. This just bodes the question, at what point will the shorts be shorting shares that they have already shorted. Its possible this is already happening. Much of their enthusiasm is probably predicated on the logic that the company will report a similar quarter as the previous ones and that they'll be able to get weak hands to sell out with some pressure. The selling pressure of late has been met with equally strong buying pressure. The shares trading on the Nasdaq have been in a very narrow range. For the sake of simplicity if we assume that 42 million shares are available for trading on Nasdaq. Out of that 42 million shares, I estimate that 32 million are held by funds leaving 10 million shares left for the hoi polloi. Shorters have already sold over 10 million shares, which means that should there be any kind of news that generates real excitement, ie, revenue generation or supply contracts, they will be competing for an ever shrinking number of shares. Many will continue to short all the way up hoping that the stock will fall after the excitement dies down, but with so few shares truly available, they will have no place to go but back into the market. We know that the PR machine is primed and ready to go once the company is ready to announce some big news. The countdown clock may have already started.

I note

The comments regarding the stock associated with JP Morgan buying were not made by JP Morgan, but by the blog author, Stuart Fine. Stuart continues to ramp this stock and claim conspiracy against shorters believing a short squeeze is imminent. He has for a very long time. The guy is a nobody with no qualifications nor authority to making any judgement on UNS. If you are taking advice from this blubber, you should take stock.

I assume you simply cut and past this from some other site.

 

[pacestick]

maybe but did he falsify the link to the sec Or to put it another way does JP Morgan buy 8.8% of a company going broke

 

[Sean K]

Last quarters financials out in Feb and they lost another $14m in the quarter. Good guess kennas.

Net capital deficit moves to $200m. That's right, the company has made an aggregate loss of $200m since it started operating. And they sell NOTHING!

And, how do you fix losing money? Well, instead of selling your product, you go to the market!!

You issue stock!! $10m to some random financier that I'm not bothered to research. Would not be surprised if they had links to one of the stock brokers who has managed their last few raisings.

That $10m will go a long way to paying Alan's salary this year.

 

[Sean K]

Another promise of revenue.

We'll come back to this, I'm sure.

Unilife Signs Long-Term Customization and Commercial Supply Agreement for EZMix Dual Chamber Syringe
***

15-Year Contract Expected to Generate up to $110 Million, with Revenue Starting Immediately Unilife to Receive a Royalty of Net Drug Sales in Exchange for Exclusivity Rights

York, PA (April 9, 2013) Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS) today announced the signing of a Customization and Commercial Supply Agreement with a U.S. pharmaceutical company (the “Customer”) for the EZMixTM dual-chamber syringe.

Unilife will supply the Customer with a customized device from its EZMix platform of dual-chamber delivery systems (“EZMix” or the “device”) for use with a lyophilized drug (the “Drug”) that requires mixing at the time of injection. The Drug, which is a proprietary version of an approved therapy, is entering late-stage clinical development with the Customer planning an accelerated pathway to U.S. regulatory approval.

Unilife expects to generate up to $110 million in revenue during the 15-year agreement based upon a customization and production scale-up program, commercial device sales and a royalty of net drug sales. Unilife will immediately begin to generate revenues under the program.

The Customer will pay Unilife approximately $3 million over a 12 to 24-month period for the customization and supply of prefilled EZMix devices for scheduled activities including human clinical drug trials and compatibility testing. Unilife will receive an additional $3 million from the Customer to fund the production scale-up of high-volume assembly equipment to manufacture the customized device at commercial volumes.

A 15 year agreement for a drug going through clinical development.

 

[Sean K]

UNS now resorting to paying for services by issuing warrants for common stock.

150,000 shares issued to a vendor providing services to Unilife (in lieu of cash)

 

[Sean K]

Conference call tomorrow on their quarterly.

They made $49k in 'receipts from customers'.

Outgoings $2.2m in R&D, and $2.6m in 'other working capital'. Read: 'exorbitant salaries and free options issued to staff for not actually doing very much.'

LOL

And they're going to the market for more cash to pay for their 'other working capital'.

From Uncle Alan:

I am therefore pleased to advise that we have agreed to preliminary terms with a leading U.S. life science financing firm for a debt funding program that we expect to finalize shortly. Combined with the anticipated revenue to be generated from new and existing customer agreements, we expect this medium-term debt program to strengthen our balance sheet, reduce the need for a secondary stock offering and thereby minimize potential dilution to existing shareholders.

 

[Sean K]

Up 44% today based on losing about $10m again, and the standard promises of 'hyper growth.'

This is just a bunch of BS until we actually see the receipts. There is NOTHING new in todays announcement. More hollow broken promises should be expected.

Lets see that immediate revenue Alan.

“Having long said that 2013 would be the inflection point for our business, I am pleased to have turned the corner. We are now entering a period of hyper-growth, and expect to generate accelerating, recurring revenue from an expanding base of customers,” stated Mr. Alan Shortall, CEO of Unilife.

“Last month, we announced the first in a series of agreements with immediate revenue. This 15-year customization and supply contact for the EZMix dual-chamber syringe is with a U.S. based pharmaceutical company that we expect will generate up to $110 million in cumulative revenue.

“We are getting ready to announce our first major long-term supply contract for the Unifill syringe. This is a significant multi-year commercial supply contract with a major pharmaceutical customer that generates revenue immediately. Negotiations for this agreement are complete and all terms have been agreed upon, with the execution copy now being routed for signature by both parties. I expect this agreement will establish Unilife as one of the leading suppliers of prefilled syringes in our industry.

“With so many transformational agreements generating immediate revenue, we have no intention of doing any secondary stock offering that would cause significant dilution to existing shareholders.

 

[pacestick]

short squeeze now on nasdaq has past asx equivalent price. Will obviously settle when the shorts have been burnt to ashes.

 

[pacestick]

57.45% rise on ASX EQUIVALENT NASDAQ PRICE NOW ABOUT $1.44 behind should jump again tonight may even start tomorrow on the asx above $1.00 This spike will obviously take some time to work through

 

[habanero]

Is pulling back a littlle now. Some people want to see the 'hyper revenue' growth and the billion dollar deal signed. It's not enough for the CEO to say that terms have been agreed and it will be signed by next week (docos being routed for signature). I think I will buy later today.